Arthrosi Therapeutics Stock

www.arthrosi.com/Healthcare / BioTech & PharmaFounded: 2018

Arthrosi Therapeutics, a clinical-stage biotech firm, is committed to developing therapies for gout and chronic kidney disease. Their leading drug candidate, AR882, has shown unprecedented sustained urate-lowering effects in gout patients. Additionally, AR882 can potentially treat a broad spectrum of renal-impaired patients suffering from gout and tophaceous gout, aiming to improve patient outcomes in these challenging conditions significantly.

Register To Buy and Sell Shares

For more details on financing and valuation for Arthrosi Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Arthrosi Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Arthrosi Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Arthrosi Therapeutics investors also invested in these private companies

Reichstein Biotech
Guangrun Health Industry
Heda Ventures
Linghang Ventures
Changrong Capital
FengHe Fund Management
LTS Capital Advisors
Viva Biotech
JMCR Family Office

Team

Management Team

Litain Yeh Ph.D
Co-Founder & Chief Executive Officer
Philip Moody
Chief Financial Officer
Shunqi Yan Ph.D
Co-Founder & Chief Operating Officer
Robert Keenan MD
Chief Medical Officer

Frequently Asked Questions About Arthrosi Therapeutics’ Stock

plusminus
Can you buy Arthrosi Therapeutics’ stock?
Arthrosi Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Arthrosi Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Arthrosi Therapeutics’ stock?
Yes, you can sell stock of a private company like Arthrosi Therapeutics. Forge can help you sell your Arthrosi Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Arthrosi Therapeutics’ stock price?
Arthrosi Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Arthrosi Therapeutics’ private market stock price with Forge Data.
plusminus
What is Arthrosi Therapeutics’ stock ticker symbol?
Arthrosi Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Arthrosi wins $75m in Series D financing
Arthrosi Therapeutics, a biotechnology company specialising in gout treatment, has successfully secured $75m in Series D financing. Led by Guangrun Health Industry, the financing round was supported by several investors, including ApicHope Pharmaceuticals subsidiary Reichstein Biotech.
Updated on: Apr 20, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.